請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27399
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 宋鴻樟(Fung-Chang Sung),李源德(Yuan-Teh Lee),簡國龍(Kuo-Liong Chien),張靜文(Ching-Wen Chang) | |
dc.contributor.author | Pei-Chun Chen | en |
dc.contributor.author | 陳培君 | zh_TW |
dc.date.accessioned | 2021-06-12T18:03:40Z | - |
dc.date.available | 2010-02-19 | |
dc.date.copyright | 2008-02-19 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-01-21 | |
dc.identifier.citation | 1.Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898-904.
2.Bernal-Pacheco O, Roman GC. Environmental vascular risk factors: new perspectives for stroke prevention. J Neurol Sci. 2007;262:60-70. 3.Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2003;2:43-53. 4.Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340:115-126. 5.Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004;29:439-493. 6.Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Jr., Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511. 7.Forouhi NG, Sattar N. CVD risk factors and ethnicity--a homogeneous relationship? Atheroscler Suppl. 2006;7:11-19. 8.Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol. 2004;93:1238-1242. 9.Anand SS, Razak F, Yi Q, Davis B, Jacobs R, Vuksan V, Lonn E, Teo K, McQueen M, Yusuf S. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol. 2004;24:1509-1515. 10.Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, Emsley HC, Forconi S, Hopkins SJ, Masotti L, Muir KW, Paciucci A, Papa F, Roncacci S, Sander D, Sander K, Smith CJ, Stefanini A, Weber D. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke. 2005;36:1316-1329. 11.Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006;145:35-42. 12.Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428. 13.Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr., Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752. 14.Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol. 2006;97:3A-11A. 15.Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109:2818-2825. 16.Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391-397. 17.Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Sr., Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004;110:380-385. 18.Hu HH, Sheng WY, Chu FL, Lan CF, Chiang BN. Incidence of stroke in Taiwan. Stroke. 1992;23:1237-1241. 19.Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension. 2004;44:6-11. 20.Scott J. Pathophysiology and biochemistry of cardiovascular disease. Curr Opin Genet Dev. 2004;14:271-279. 21.Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109:II2-10. 22.lake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002;252:283-294. 23.Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM. 2003;96:793-807. 24.Sandhu RS, Petroni DH, George WJ. Ambient particulate matter, C-reactive protein, and coronary artery disease. Inhal Toxicol. 2005;17:409-413. 25.Backes JM, Howard PA, Moriarty PM. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother. 2004;38:110-118. 26.Khuseyinova N, Imhof A, Trischler G, Rothenbacher D, Hutchinson WL, Pepys MB, Koenig W. Determination of C-reactive protein: comparison of three high-sensitivity immunoassays. Clin Chem. 2003;49:1691-1695. 27.Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003;108:2292-2297. 28.Boden-Albala B. Current understanding of multiple risk factors as the metabolic syndrome: distillation or deconstruction. Semin Neurol. 2006;26:108-116. 29.Tataranni PA, Ortega E. A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes. 2005;54:917-927. 30.Lim S, Lee HK, Kimm KC, Park C, Shin C, Cho NH. C-reactive protein level as an independent risk factor of metabolic syndrome in the Korean population. CRP as risk factor of metabolic syndrome. Diabetes Res Clin Pract. 2005;70:126-133. 31.Choi EY, Park EH, Cheong YS, Rheem I, Park SG, Yoo S. Association of C-reactive protein with the metabolic risk factors among young and middle-aged Koreans. Metabolism. 2006;55:415-421. 32.Matsushita K, Yatsuya H, Tamakoshi K, Wada K, Otsuka R, Takefuji S, Sugiura K, Kondo T, Murohara T, Toyoshima H. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol. 2006;26:871-876. 33.Ye X, Yu Z, Li H, Franco OH, Liu Y, Lin X. Distributions of C-reactive protein and its association with metabolic syndrome in middle-aged and older Chinese people. J Am Coll Cardiol. 2007;49:1798-1805. 34.Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002;25:2016-2021. 35.Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia. 2004;47:1403-1410. 36.Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-1482. 37.Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204. 38.Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397. 39.Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PH, Polak JF, Sutton-Tyrrell K, Herrington DM, Price TR, Cushman M. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003;108:166-170. 40.Curb JD, Abbott RD, Rodriguez BL, Sakkinen P, Popper JS, Yano K, Tracy RP. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation. 2003;107:2016-2020. 41.Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol. 2000;20:1047-1051. 42.Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979. 43.Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565. 44.Bos MJ, Schipper CM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM. High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study. Circulation. 2006;114:1591-1598. 45.Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003;108:2317-2322. 46.Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, D'Agostino RB, Franzblau C, Wilson PW. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke. 2001;32:2575-2579. 47.Wakugawa Y, Kiyohara Y, Tanizaki Y, Kubo M, Ninomiya T, Hata J, Doi Y, Okubo K, Oishi Y, Shikata K, Yonemoto K, Maebuchi D, Ibayashi S, Iida M. C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke in a general Japanese population: the Hisayama Study. Stroke. 2006;37:27-32. 48.Chen HJ, Bai CH, Yeh WT, Chiu HC, Pan WH. Influence of metabolic syndrome and general obesity on the risk of ischemic stroke. Stroke. 2006;37:1060-1064. 49.Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT. Metabolic syndrome as a risk factor for coronary heart disease and stroke: an 11-year prospective cohort in Taiwan community. Atherosclerosis. 2007;194:214-221. 50.Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Murphy MB, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Shepherd J. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation. 2007;115:981-989. 51.van der Meer IM, de Maat MP, Kiliaan AJ, van der Kuip DA, Hofman A, Witteman JC. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med. 2003;163:1323-1328. 52.O'Leary DH, Polak JF, Wolfson SK, Jr., Bond MG, Bommer W, Sheth S, Psaty BM, Sharrett AR, Manolio TA. Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke. 1991;22:1155-1163. 53.Simon A, Gariepy J, Chironi G, Megnien JL, Levenson J. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens. 2002;20:159-169. 54.Zureik M, Ducimetiere P, Touboul PJ, Courbon D, Bonithon-Kopp C, Berr C, Magne C. Common carotid intima-media thickness predicts occurrence of carotid atherosclerotic plaques: longitudinal results from the Aging Vascular Study (EVA) study. Arterioscler Thromb Vasc Biol. 2000;20:1622-1629. 55.Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997;96:1432-1437. 56.Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azen SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262-269. 57.Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459-467. 58.van der Meer IM, de Maat MP, Bots ML, Breteler MM, Meijer J, Kiliaan AJ, Hofman A, Witteman JC. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2002;22:838-842. 59.Blackburn R, Giral P, Bruckert E, Andre JM, Gonbert S, Bernard M, Chapman MJ, Turpin G. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol. 2001;21:1962-1968. 60.Makita S, Nakamura M, Hiramori K. The association of C-reactive protein levels with carotid intima-media complex thickness and plaque formation in the general population. Stroke. 2005;36:2138-2142. 61.Magyar MT, Szikszai Z, Balla J, Valikovics A, Kappelmayer J, Imre S, Balla G, Jeney V, Csiba L, Bereczki D. Early-onset carotid atherosclerosis is associated with increased intima-media thickness and elevated serum levels of inflammatory markers. Stroke. 2003;34:58-63. 62.Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, Hofman A, Witteman JC. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 1999;19:1986-1991. 63.Winbeck K, Kukla C, Poppert H, Klingelhofer J, Conrad B, Sander D. Elevated C-reactive protein is associated with an increased intima to media thickness of the common carotid artery. Cerebrovasc Dis. 2002;13:57-63. 64.Wang TJ, Nam BH, Wilson PW, Wolf PA, Levy D, Polak JF, D'Agostino RB, O'Donnell CJ. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002;22:1662-1667. 65.Hee Choi S, Chang Kim H, Woo Ahn C, Keun Cho H, Soo Cha B, Chung YS, Woo Lee K, Chul Lee H, Bum Huh K, Kim DJ. Is high-sensitivity C-reactive protein associated with carotid atherosclerosis in healthy Koreans? Eur J Cardiovasc Prev Rehabil. 2005;12:548-554. 66.Bowden DW, Lange LA, Langefeld CD, Brosnihan KB, Freedman BI, Carr JJ, Wagenknecht LE, Herrington DM. The relationship between C-reactive protein and subclinical cardiovascular disease in the Diabetes Heart Study (DHS). Am Heart J. 2005;150:1032-1038. 67.Lorenz MW, Karbstein P, Markus HS, Sitzer M. High-sensitivity C-reactive protein is not associated with carotid intima-media progression: the carotid atherosclerosis progression study. Stroke. 2007;38:1774-1779. 68.Ahluwalia N, Drouet L, Ruidavets JB, Perret B, Amar J, Boccalon H, Hanaire-Broutin H, Ferrieres J. Metabolic syndrome is associated with markers of subclinical atherosclerosis in a French population-based sample. Atherosclerosis. 2006;186:345-353. 69.Iglseder B, Cip P, Malaimare L, Ladurner G, Paulweber B. The metabolic syndrome is a stronger risk factor for early carotid atherosclerosis in women than in men. Stroke. 2005;36:1212-1217. 70.Lee Y, Lin RS, Sung FC, Yang C, Chien K, Chen W, Su T, Hsu H, Huang Y. Chin-Shan Community Cardiovascular Cohort in Taiwan-baseline data and five-year follow-up morbidity and mortality. J Clin Epidemiol. 2000;53:838-846. 71.Vukovich TC, Mustafa S, Rumpold H, Wagner O. Evaluation of a turbidimetric Denka Seiken C-reactive protein assay for cardiovascular risk estimation and conventional inflammation diagnosis. Clin Chem. 2003;49:511-512. 72.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497. 73.Yen ML, Yang CY, Yen BL, Ho YL, Cheng WC, Bai CH. Increased high sensitivity C-reactive protein and neutrophil count are related to increased standard cardiovascular risk factors in healthy Chinese men. Int J Cardiol. 2006;110:191-198. 74.Shiesh SC, Chou TC, Lin XZ, Kao PC. Determination of C-reactive protein with an ultra-sensitivity immunochemiluminometric assay. J Immunol Methods. 2006;311:87-95. 75.Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, Wians FH, Jr., Grundy SM, de Lemos JA. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol. 2005;46:464-469. 76.Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, Nakamura Y, Itoh Y, Kajii E. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population : Jichi Medical School Cohort Study. Am J Epidemiol. 2001;153:1183-1190. 77.Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB, Jr., Herrington DM. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J. 2006;152:593-598. 78.Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83:847-850. 79.Onat A, Avci GS, Barlan MM, Uyarel H, Uzunlar B, Sansoy V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord. 2004;28:1018-1025. 80.Su TC, Jeng JS, Chien KL, Sung FC, Hsu HC, Lee YT. Hypertension status is the major determinant of carotid atherosclerosis: a community-based study in Taiwan. Stroke. 2001;32:2265-2271. 81.Chen CC, Chung MY, Jeng JS, Yip PK, Hwang BS, Chang YC. A scoring system for evaluation of the extent of extracranial carotid atherosclerosis with B-mode imaging. Acta Neurol Sin. 1995;4:29-33. 82.Jeng JS, Chung MY, Yip PK, Hwang BS, Chang YC. Extracranial carotid atherosclerosis and vascular risk factors in different types of ischemic stroke in Taiwan. Stroke. 1994;25:1989-1993. 83.Su TC, Jeng JS, Wang JD, Torng PL, Chang SJ, Chen CF, Liau CS. Homocysteine, circulating vascular cell adhesion molecule and carotid atherosclerosis in postmenopausal vegetarian women and omnivores. Atherosclerosis. 2006;184:356-362. 84.Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Fatar M, Hernandez Hernandez R, Jaff M, Kownator S, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS, Zannad F, Zureik M. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007;23:75-80. 85.Spence JD, Hegele RA. Noninvasive phenotypes of atherosclerosis: similar windows but different views. Stroke. 2004;35:649-653. 86.Willeit J, Kiechl S, Oberhollenzer F, Rungger G, Egger G, Bonora E, Mitterer M, Muggeo M. Distinct risk profiles of early and advanced atherosclerosis: prospective results from the Bruneck Study. Arterioscler Thromb Vasc Biol. 2000;20:529-537. 87.Hegele RA. The pathogenesis of atherosclerosis. Clin Chim Acta. 1996;246:21-38. 88.Pollex RL, Al-Shali KZ, House AA, Spence JD, Fenster A, Mamakeesick M, Zinman B, Harris SB, Hanley AJ, Hegele RA. Relationship of the metabolic syndrome to carotid ultrasound traits. Cardiovasc Ultrasound. 2006;4:28. 89.Ishizaka N, Ishizaka Y, Hashimoto H, Toda E, Nagai R, Yamakado M. Metabolic syndrome may not associate with carotid plaque in subjects with optimal, normal, or high-normal blood pressure. Hypertension. 2006;48:411-417. 90.Irace C, Cortese C, Fiaschi E, Carallo C, Sesti G, Farinaro E, Gnasso A. Components of the metabolic syndrome and carotid atherosclerosis: role of elevated blood pressure. Hypertension. 2005;45:597-601. 91.Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab. 2003;88:2470-2478. 92.Kalish GM, Barrett-Connor E, Laughlin GA, Gulanski BI. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial. J Clin Endocrinol Metab. 2003;88:1646-1652. 93.Higashi Y, Sanada M, Sasaki S, Nakagawa K, Goto C, Matsuura H, Ohama K, Chayama K, Oshima T. Effect of estrogen replacement therapy on endothelial function in peripheral resistance arteries in normotensive and hypertensive postmenopausal women. Hypertension. 2001;37:651-657. 94.DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845. 95.McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, Ballantyne CM, Heiss G. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005;28:385-390. 96.Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:2644-2650. 97.Najarian RM, Sullivan LM, Kannel WB, Wilson PW, D'Agostino RB, Wolf PA. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med. 2006;166:106-111. 98.McNeill AM, Katz R, Girman CJ, Rosamond WD, Wagenknecht LE, Barzilay JI, Tracy RP, Savage PJ, Jackson SA. Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study. J Am Geriatr Soc. 2006;54:1317-1324. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27399 | - |
dc.description.abstract | 發炎指標─高敏感度C反應蛋白(high sensitivity C-reactive protein, CRP)為近十年來受研究者關注的新興心血管疾病危險因子,也與代謝症候群有顯著相關。研究者進而建議將CRP作為例行心血管疾病早期預測指標。本研究以參與1994-1995年金山心血管世代追蹤研究的金山地區居民,探討以下三個主要問題。
一、影響CRP濃度的人口學與可修飾的心血管危險因子 (橫斷式研究 1) 背景:CRP濃度為慢性低強度的發炎反應之良好指標。本研究探討人口學因素及心血管疾病的危險因子是否與此程度的發炎反應有關。方法與結果:研究對象為具有CRP與代謝症候群完整資料的916位金山居民。單變項分析顯示,年齡、性別、婚姻狀況、身體質量指數、腰圍、三酸甘油脂、高血壓、糖尿病與代謝症候群與較高的CRP濃度有關。複回歸模式(multiple linear regression model)顯示,年齡、腰圍與代謝症候群與CRP濃度有關。結論:本研究與過去的研究一致,顯示CRP與代謝症候群的相關性。在此族群,中央肥胖與CRP濃度之相關較身體質量指數強。 二、CRP、代謝症候群與頸動脈硬化的相關 (橫斷式研究 2) 背景:過去研究顯示CRP與代謝症候群與頸動脈硬化有關,但其關係在不同硬化指標並不一致且有性別差異。方法與結果:本研究分別探討男性(456人)與女性(354人)居民之血漿(plasma) CRP濃度、代謝症候群與頸動脈硬化之相關。頸動脈硬化的評估指標為頸動脈增厚(thicker intima-media thickness [IMT] on the common carotid artery [CCA], IMT > 1.0 mm)及出現頸動脈粥狀硬化斑塊(presence of plaque on the extracranial carotid artery)。研究對象中,女性的CRP中位數濃度與代謝症候群盛行率高於男性。複回歸分析結果(multiple logistic regression model)顯示,有代謝症候群的女性較傾向頸動脈增厚(odds ratio [OR] = 2.07),男性則無此現象。然而,相較於CRP濃度小於1 mg/L者,濃度高於3 mg/L的男性出現粥狀硬化斑塊機會較高 (OR=1.99);若男性同時具有代謝症候群者出現硬化斑塊的機會更高(OR=2.22)。結論:本研究顯示女性的頸動脈增厚與代謝症候群相關;男性之頸動脈粥狀硬化斑塊的出現與CRP濃度有關,且代謝症候群的出現增強此關係。 三、 CRP、代謝症候群與腦中風的相關 (重疊病例對照研究) 背景: CRP對於發生腦中風的影響及其是否改善已知危險因子對心血管疾病的預測能力還未定論。此外,相關研究多數在白人裔族進行,然而華人的CRP中位數濃度顯著低於其他種族。研究亦顯示CRP對於代謝症候群與心血管疾病的關係具有相加效果(additive effect)。方法及結果:本研究以自1994 (或1995)年至2005年為止,65位新發生中風病患為研究組,並隨機選出109位在此期間從未發生中風或冠狀動脈心臟病者為對照組,分析這些研究對象在1994-1995年時的血漿CRP濃度及代謝症候群狀況對其後發生中風的影響。病例組的基線(baseline)血液CRP濃度高於對照組(1.3對1.1 mg/L, p = 0.007)。多變項回歸分析(multiple logistic regression model)結果顯示,相較於對照組CRP濃度分布三分位之最低分位者(<= 0.7 mg/L),CRP濃度於最高分位者(> 1.3 mg/L)發生中風的危險性為2.55 (95%信賴區間1.05-6.23),在模式中加入代謝症候群並不影響結果。以Cox回歸模式(Cox proportional hazard model)分析並未改變主要結果。以the receiver operating characteristics curves區域下面積分析結果顯示,相較於已知危險因子(年齡、性別、高血壓、糖尿病、總膽固醇及腰圍)(0.68),CRP、代謝症候群(皆為0.69)或合併兩者(0.70)皆未顯著增加對於疾病的區別能力。結論:本研究在華人族群印證了較高CRP濃度為發生中風的危險因子,但CRP、代謝症候群及兩者共同對於中風發生的預測能力並未優於已知危險因子。 | zh_TW |
dc.description.abstract | This study consisted of three sub-projects to investigate the association between C-reactive protein (CRP) levels, the metabolic syndrome (MetS) and cardiovascular risk in middle-aged and older Taiwanese adults. Three major aims were achieved using two types of study designs for the three studies. The nested case-control study evaluated whether CRP levels and MetS predicted stroke risk, in addition to the traditional cardiovascular disease risk factors. The other two parts of the study used a cross-sectional design to examine the association of CRP levels and MetS with carotid atherosclerosis by sex, and investigated the demographic and modifiable correlates for the CRP levels.
Study subjects were participants in the 1994-1995 follow-up survey of the Chin-Shan Community Cardiovascular Cohort study. The cross-sectional study included 810 subjects who received measurements for CRP levels, MetS components, and ultrasound examinations for common carotid artery (CCA) intima-media thickness (IMT) and extra-cranial carotid artery plaques. However, for the study aimed to investigate CRP level correlates, participants with complete information on CRP were included regardless of the availability of ultrasound examination data (n=916). The individuals selected for the nested case-control study consisted of 65 first-ever strokes and 109 controls free of stroke during the 10-year follow-up period, from 1994 or 1995 until 2005. CRP levels in the plasma were determined using a high-sensitivity immunoturbidimetric assay. MetS was defined according to criteria from the U.S. National Cholesterol Education Program Adult Treatment PanelⅢ. Results of the cross-sectional study 1: Age, sex, marital status, body mass index, waist circumference, triglycerides, hypertension, diabetes and MetS were associated with CRP levels in univariate analyses. However, age, waist circumference and MetS were remained as the significant predictors of CRP levels in multiple linear regression analyses. Results of the cross-sectional study 2: Women had higher median CRP (1.3 vs. 1.1 mg/L) and higher MetS prevalence than men (58.8 vs. 34.2%). Thicker IMT was associated with MetS in women (adjusted odds ratio [OR] 2.07, 95 % confidence interval [CI] 1.04-4.11) but not in men. Compared to participants with CRP < 1 mg/L, men with CRP > 3 mg/L had an elevated OR with the plaque presence (OR 1.99, 95 % CI 1.10-3.61) but not women. The odds ratio for the artery plague increased to 2.20 (p = 0.046) for individuals with MetS and CRP level > 3 mg/L, compared with men with CRP < 1 mg/L and no MetS. Results of the nested case-control study: The median CRP values in stroke cases and control subjects were 1.5 mg/L and 1.1 mg/L, respectively (p = 0.007). The logistic regression models showed that the multivariate-adjusted stroke OR was 2.55 (95% CI 1.05-6.23) for subjects at the top tertile CRP level compared with the bottom tertile levels in the controls. The risk was not attenuated after further adjustment for MetS or for hypertension. The risk for stroke associated with MetS was eliminated after including hypertension and diabetes in the model. The estimated risks were weaker, but the main results remained, when the Cox proportional hazard model was used for analyses. The area under receiver operating characteristic curves for traditional risk factors (0.68) was improved little by adding CRP or MetS (both 0.69) or the combination of these two variables (0.70). In conclusion, CRP is an independent risk factor associated with stroke. But, both CRP and MetS provide limited improvement for the stroke risk discrimination beyond the traditional risk factors. In the sub-clinical stage of the disease, CRP levels and MetS correlate with distinct phenotypes of carotid atherosclerosis among men and women. MetS is related to thicker IMT in women, while elevated CRP is associated with the presence of plaque in men. This association is enhanced by MetS. Finally, in addition to MetS, central obesity is strongly associated with CRP levels independent of BMI in this population. | en |
dc.description.provenance | Made available in DSpace on 2021-06-12T18:03:40Z (GMT). No. of bitstreams: 1 ntu-97-D92844002-1.pdf: 581618 bytes, checksum: c30c484d517cc69608583f5ca8c81293 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 誌謝.....i
中文摘要.....ii Abstract.....iv Chapter 1 Introduction.....1 1.1 Background.....1 1.2 Specific Aims.....4 Chapter 2 Literature Review.....6 2.1 Inflammation in Atherosclerotic Process and the Role of C-Reactive Protein.....6 2.2 Association Between C-Reactive Protein and Metabolic Syndrome.....10 2.3 Association of C-Reactive Protein and Metabolic Syndrome with Stroke: epidemiological evidence on primary prevention.....13 2.4 Association of C-Reactive Protein and Metabolic Syndrome with Carotid Atherosclerosis.....21 Chapter 3 Cross-Sectional Study 1: the Correlates of Levels of C-Reactive Protein.....24 3.1 Methods.....24 3.1.1 Study Population.....24 3.1.2 C-Reactive Protein Determination.....26 3.1.3 Definitions of the Metabolic Syndrome and Other Risk Factors.....26 3.1.4 Statistical Analysis.....27 3.2 Results.....29 3.3 Discussion.....38 Chapter 4 Cross-Sectional Study 2: the Association Between C-Reactive Protein, the Metabolic Syndrome and Carotid Atherosclerosis.....42 4.1 Methods.....42 4.1.1 Selection of Subjects.....42 4.1.2 Carotid Ultrasonography.....43 4.1.3 Statistical Analysis.....44 4.2 Results.....46 4.3 Discussion.....55 Chapter 5 Nested Case-Control Study: the Association of C-Reactive Protein and the Metabolic Syndrome with Stroke.....60 5.1 Methods.....60 5.1.1 Selection of Stroke Cases and Control Subjects.....60 5.1.2 Statistical Analysis.....61 5.2 Results.....63 5.3 Discussion.....73 Chapter 6 Conclusions and Future Perspectives.....79 References.....82 Appendixes.....93 Appendix A......93 Appendix B......101 Appendix C......104 Appendix D......108 | |
dc.language.iso | en | |
dc.title | C-反應蛋白、代謝症候群與頸動脈硬化之相關及發生腦中風之危險性: 金山心血管世代研究 | zh_TW |
dc.title | C-Reactive Protein and the Metabolic Syndrome in Relation to Carotid Atherosclerosis and Stroke Risk:
The Chin-Shan Community Cardiovascular Cohort Study | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 李中一(Chung-Yi Li),張淑惠(Shu-Hui Chang) | |
dc.subject.keyword | C-反應蛋白,代謝症候群,頸動脈內-中膜厚度,頸動脈粥狀硬化斑塊,腦中風,華人, | zh_TW |
dc.subject.keyword | C-reactive protein,metabolic syndrome,carotid intima media thickness,carotid artery plaque,stroke,Chinese, | en |
dc.relation.page | 109 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-01-22 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 環境衛生研究所 | zh_TW |
顯示於系所單位: | 環境衛生研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 567.99 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。